RxDoctor Payments Data

Haley Pope, DO

Family Medicine · Clinton Township, MINPI 1578685921

Payments from drug & device makers

$6,367in general payments, 2019–2025

Across 377 payments — averaging $16.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Lilly USA, LLC$1K
  • Amgen$451
  • Pfizer$446
  • Boehringer Ingelheim$310
  • Bayer$300
  • plus $2K from 29 others

What the payments were for

  • Food & beverage$6,32799%
  • Education$401%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,367 in reported general payments places this provider in the 90th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$62,415
Medicare patients
116
Services billed
1,296

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide42$58,897
OzempicSemaglutide36$49,429
Trelegy ElliptaFluticasone/Umeclidin/Vilanter53$39,796
JardianceEmpagliflozin34$38,823
InvokanaCanagliflozin21$35,121
MounjaroTirzepatide28$30,403
FarxigaDapagliflozin Propanediol22$27,919
EliquisApixaban17$23,158
JanuviaSitagliptin Phosphate13$18,522
RybelsusSemaglutide12$15,062
KerendiaFinerenone11$12,658
LinzessLinaclotide12$6,729
Novolog FlexpenInsulin Aspart15$3,745
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$2,593
Atorvastatin Calcium255$2,497

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$1,183$89,30070 claims
Novo NordiskOzempic, Rybelsus$1,220$64,49148 claims
GSKTrelegy Ellipta$290$39,79653 claims
Boehringer IngelheimJardiance$310$38,82334 claims
Johnson & JohnsonInvokana$70$35,12121 claims
AstraZenecaFarxiga$280$27,91922 claims
PfizerEliquis$446$23,15817 claims
MerckJanuvia$105$18,52213 claims
BayerKerendia$300$12,65811 claims
AbbVieLinzess$226$6,72912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Clinton Township

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →